<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 09 Feb 2021 16:21:22 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>公安部:2020年出生并户籍登记的新生儿共1003.5万</title><link>https://mp.weixin.qq.com/s/sNd7hHmliA8fgMVz2YruMw</link><description></description><content:encoded><![CDATA[公安部:2020年出生并户籍登记的新生儿共1003.5万]]></content:encoded><pubDate>Tue, 09 Feb 2021 15:19:07 +0800</pubDate></item><item><title>茅台染指后浪 Oh It&#39;s Moutai</title><link>https://mp.weixin.qq.com/s/cEyTDM2zm-8CKZ0zX9OfLA</link><description></description><content:encoded><![CDATA[茅台染指后浪 Oh It's Moutai]]></content:encoded><pubDate>Tue, 09 Feb 2021 15:19:07 +0800</pubDate></item><item><title>维布妥昔单抗（BV）日本上市后临床研究结果</title><link>https://mp.weixin.qq.com/s/ilVfA77Ah7HvoNWnjoe6mg</link><description></description><content:encoded><![CDATA[维布妥昔单抗（BV）日本上市后临床研究结果]]></content:encoded><pubDate>Tue, 09 Feb 2021 15:19:07 +0800</pubDate></item><item><title>CD30学院 | 邱立华教授——2020ASH好声音 DLBCL最新进展</title><link>https://mp.weixin.qq.com/s/KDejCYXNjDrinYSc-hHzXA</link><description></description><content:encoded><![CDATA[CD30学院 | 邱立华教授——2020ASH好声音 DLBCL最新进展]]></content:encoded><pubDate>Tue, 09 Feb 2021 15:19:07 +0800</pubDate></item><item><title>周彩存教授专访:与您一同聚焦EGFR Exon 20ins突变和ALK阳性NSCLC治疗进展</title><link>https://mp.weixin.qq.com/s/AlEA3CDT4c43UyHhBZiSCQ</link><description></description><content:encoded><![CDATA[周彩存教授专访:与您一同聚焦EGFR Exon 20ins突变和ALK阳性NSCLC治疗进展]]></content:encoded><pubDate>Mon, 08 Feb 2021 13:35:39 +0800</pubDate></item><item><title>周期如此短，医学如何做？</title><link>https://mp.weixin.qq.com/s/fRbZsBLwz5jDOtm1w2zMAw</link><description></description><content:encoded><![CDATA[周期如此短，医学如何做？]]></content:encoded><pubDate>Mon, 08 Feb 2021 13:35:39 +0800</pubDate></item><item><title>NEJM:一项基于人群的乳腺癌相关基因研究</title><link>https://mp.weixin.qq.com/s/-dO2Pmi212IB02bx5rwslw</link><description></description><content:encoded><![CDATA[NEJM:一项基于人群的乳腺癌相关基因研究]]></content:encoded><pubDate>Sun, 07 Feb 2021 12:39:16 +0800</pubDate></item><item><title>【JAMA Oncology】肝癌免疫治疗药物汇总及展望</title><link>https://mp.weixin.qq.com/s/7TPtbPJGpgtcLzuCSR_lqw</link><description></description><content:encoded><![CDATA[【JAMA Oncology】肝癌免疫治疗药物汇总及展望]]></content:encoded><pubDate>Sun, 07 Feb 2021 12:39:16 +0800</pubDate></item><item><title>专访 | 鲍立教授：多发性骨髓瘤的不良预后因素—高钙血症的故事比你想象的更复杂！</title><link>https://mp.weixin.qq.com/s/JHelWmw5-nS0H-UBamZ33Q</link><description></description><content:encoded><![CDATA[专访 | 鲍立教授：多发性骨髓瘤的不良预后因素—高钙血症的故事比你想象的更复杂！]]></content:encoded><pubDate>Sat, 06 Feb 2021 20:12:01 +0800</pubDate></item><item><title>第二届武田中国血液肿瘤卓越实践论坛成功举行</title><link>https://mp.weixin.qq.com/s/siyRHNggPDUcYNIvsO2eqQ</link><description></description><content:encoded><![CDATA[第二届武田中国血液肿瘤卓越实践论坛成功举行]]></content:encoded><pubDate>Sat, 06 Feb 2021 20:12:01 +0800</pubDate></item><item><title>武田公布2020财年Q3业绩，14个全球品牌产品增长15.4%</title><link>https://mp.weixin.qq.com/s/yhnVArhSBcp4pD748WMtHQ</link><description></description><content:encoded><![CDATA[武田公布2020财年Q3业绩，14个全球品牌产品增长15.4%]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:54:35 +0800</pubDate></item><item><title>武田制药荣登2021全球药品可及性指数榜单</title><link>https://mp.weixin.qq.com/s/erZGSDG9LrwJBknYTbR2aQ</link><description></description><content:encoded><![CDATA[武田制药荣登2021全球药品可及性指数榜单]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:54:35 +0800</pubDate></item><item><title>克唑替尼→卡帕替尼治疗MET阳性NSCLC</title><link>https://mp.weixin.qq.com/s/5wOLDmq2jiSStmxPV5Fanw</link><description></description><content:encoded><![CDATA[克唑替尼→卡帕替尼治疗MET阳性NSCLC]]></content:encoded><pubDate>Fri, 05 Feb 2021 12:54:35 +0800</pubDate></item><item><title>武田：致力于成为血友病创新治疗的领导者</title><link>https://mp.weixin.qq.com/s/F9UEENvthn_VYqP5z11INQ</link><description></description><content:encoded><![CDATA[武田：致力于成为血友病创新治疗的领导者]]></content:encoded><pubDate>Thu, 04 Feb 2021 14:47:02 +0800</pubDate></item><item><title>武田制药于2020年实现碳中和</title><link>https://mp.weixin.qq.com/s/DJRuR8DBBwBq3XCUse26Sg</link><description></description><content:encoded><![CDATA[武田制药于2020年实现碳中和]]></content:encoded><pubDate>Wed, 03 Feb 2021 22:01:46 +0800</pubDate></item><item><title>【2723】WCLC20|台湾省肺癌筛查计划研究结果出炉，力证低剂量螺旋CT在东亚人群中应用价值</title><link>https://mp.weixin.qq.com/s/rcapFeGBl1csOD-4PpV1ZA</link><description></description><content:encoded><![CDATA[【2723】WCLC20|台湾省肺癌筛查计划研究结果出炉，力证低剂量螺旋CT在东亚人群中应用价值]]></content:encoded><pubDate>Wed, 03 Feb 2021 22:01:46 +0800</pubDate></item><item><title>价值回归-国办《关于推动药品集中带量采购工作常态化制度化开展的意见》对医学事务同仁的启示</title><link>https://mp.weixin.qq.com/s/dKcf7AbA6XJYrlF2fXbKCg</link><description></description><content:encoded><![CDATA[价值回归-国办《关于推动药品集中带量采购工作常态化制度化开展的意见》对医学事务同仁的启示]]></content:encoded><pubDate>Wed, 03 Feb 2021 22:01:46 +0800</pubDate></item><item><title>NSCLC双免疫一线治疗出现不同声音</title><link>https://mp.weixin.qq.com/s/kqspTxfL9pwjnyueDZiKMQ</link><description></description><content:encoded><![CDATA[NSCLC双免疫一线治疗出现不同声音]]></content:encoded><pubDate>Tue, 02 Feb 2021 17:34:21 +0800</pubDate></item><item><title>年终评估的几个要点</title><link>https://mp.weixin.qq.com/s/EflhP4SEmGAoCn6saKMjSw</link><description></description><content:encoded><![CDATA[年终评估的几个要点]]></content:encoded><pubDate>Mon, 01 Feb 2021 18:02:48 +0800</pubDate></item><item><title>隐秘的真相:窒息的假象</title><link>https://mp.weixin.qq.com/s/4zLktBChn66T6FIpczG6cw</link><description></description><content:encoded><![CDATA[隐秘的真相:窒息的假象]]></content:encoded><pubDate>Mon, 01 Feb 2021 18:02:48 +0800</pubDate></item></channel></rss>